Publication | Open Access
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
122
Citations
27
References
2025
Year
Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov number, NCT04221477.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1